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Letter to the editor
Systemic sclerosis (SSc) is a chronic connective tissue
disease characterized by widespread microvascular dam-
age, dysregulation of fibroblasts with collagen overproduc-
tion and excessive fibrosis of the skin and internal organs,
as well as complex immune system abnormalities.1–3
Patients are classified into the diffuse cutaneous form of
SSc (dcSSc) when skin thickening extends to the trunk
and the proximal part of the limbs, and into the limited
cutaneous form (lcSSc) when skin induration is limited to
face, hands and feet.4
The heart is the major organ involved in SSc, being a poor
prognostic factor and the leading cause of mortality.5,6
Cardiac involvement is reported in 15–20% of patients
and when sensitive tools are used, it has been estimated
to occur in up to 100% of SSc patients.1,4
The aim of the present study was to investigate cardiac
involvement in different patterns of SSc in order to
identify patients at high risk of cardiopulmonary
impairment.
Methods
We retrospectively analyzed data from 241 consecutive
SSc patients referred to our University-based Rheuma-
tology Centre from January 1999 to January 2014 (F/M
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tion 10.9 7.0). In all cases, the diagnosis of SSc was done
by an expert rheumatologist on the basis of a wider panel
of clinical, serological and capillaroscopic parameters;
moreover, they satisfied the new ACR/EULAR classifi-
cation criteria.7 Patients were classified on the extent of
skin sclerosis as limited cutaneous scleroderma (lcSSc)
and diffuse cutaneous scleroderma (dcSSc).4 All patients
underwent baseline and periodically clinical evaluation,
including demographic, serological and laboratory, pul-
monary and cardiological evaluation.
The protocol was approved by Local Ethical Committee
(pr # 10693 25/05/2016). All patients signed an informed
consensus document.
Serum autoantibodies
The presence of serum autoantibodies was investigated
by means of standard techniques: antinuclear (ANA),
anticentromere (ACA) and antinucleolar antibodies by
indirect immunofluorescence on Hep-2 cell lines; anti-
extractable nuclear antigen antibodies, including anti-
Scl70, anti-Sm, anti-RNP, anti-SSA/SSB; antiphospholi-
pid antibodies; liver autoimmune profile; rheumatoid
factor and antibodies to cyclic citrullinated peptide.
Cardiac assessment
Cardiac assessment was performed every 6 months and
included clinical evaluation, ECG and Doppler echocar-
diography.8–12 Cardiac risk stratification was performed
according to Framingham Score.7 The right heart cathe-
terization, when indicated, was performed according to
current methodologies.12,13
Statistical analysis
Statistical analysis was performed using SPSS (IBM soft-
ware, New York, version 22.0). We performed a logistic
regression analysis to investigate the possible correlation
outcome and cardiopulmonary involvement.
Comparison of data between groups was performed by
ANOVA. The t-test was used to compare data within
groups. P< 0.05 was considered statistically significant.DOI:10.2459/JCM.0000000000000676
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Table 1 Clinical features, antibodies panel and biomarkers
Parameter lcSSc dcSSc P
Sex, F/M 180/29 25/7
Age (years) 51.8414.55 43.7814.14 0.0039
Follow-up duration (months) 67.1441.86 65.2536.191 ns
Disease duration (years) 117.12 10.566.42 ns
Death (%) 32 (15.30) 6 (18.75) ns
Raynaud (%) 208 (99.50) 31 (96.80) ns
Digital ulcers (%) 104 (49.76) 25 (69.70) 0.02
Myositis 9 (4.30) 7 (18.75) 0.007
Arthitis 32 (15.30) 7 (18.75) ns
SCl 70 antibodies 61 (29.00) 27 (75.00) 0.0025
ACA antibodies 88 (42.00) 3 (9.3) 0.0081
ANOA antibodies 35 (16.7) 5 (12.50) ns
ESR 51 (24.4) 18 (50) 0.05
CRP 34 (16.2) 15 (40) 0.025
Uric acid 10 (4.78) 3 (6.25) ns
Creatinine 13 (6.2) 7 (18.75) 0.04
ACA, anticentromere; ANOA, antinucleolar antibodies; CRP, C-reactive protein;
dcSSc, diffuse cutaneous form of SSc; ESR, erythrocyte sedimentation rate;
lcSSc, limited cutaneous form.Results
Thirty-two patients had dcSSc (13.27%) whereas 209
patients had lcSSc (86.73%). We did not report differ-
ences in sex and duration of disease, whereas dcSSc
patients were younger than lcSSc (43.78þ 14.14 years
vs. 51.84þ 14.55 years; P< 0.01; Table 1). The follow-up
duration was similar in the two groups of patients and
lasted 65.25 months in dcSSc and 67.14 in lcSSc (P¼ns).
Autoimmune and biomarkers pattern
SCl 70 was positive in a greater number of patients with
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Survival functions
Survival curves of patients with and without skin ulcers.a greater number of patients with lcSSc developed ACA
antibodies (P¼ 0.0081).
Patients with dcSSc showed a higher inflammatory status
with increased erythrocyte sedimentation rate and CPR
value (Table 1).
Cardiac involvement
Cardiovascular involvement at baseline was present in
107 (51.2%) patients with lcSSc and in 13 patients
(40.6%) with dcSSc. According to baseline data, we did
not find differences between the limited and the diffuse
presentation of SSc. However, the presence of skin ulcers
was predictive of cardiac involvement [odds ratio (OR)
1.2; 95% CI 1.01–1.91; P< 0.05]. Then we categorized
patients according to the presence of skin ulcers.14 Skin
ulcers were more frequent in dlSSc patients (7.9 vs. 18.1;
P¼ 0.05).
Moreover, patients with ulcers showed a greater cardiac
involvement. Specifically, they had more ECG alteration
and ischemia (36 vs. 64%; P< 0.05). Left ventricular
ejection fraction was also reduced in patients with ulcers
(60 4 vs. 58 5; P< 0.01) and diastolic dysfunction
showed deterioration during follow-up. Patients with skin
ulcers had a greater cardiac mortality with a trend to
significance (11.4 vs. 19.7%; P¼ 0.08; Fig. 1).
Comment
The present article evaluated the cardiac involvement in
patients affected by SSc, in order to identify high-risk
patients. Cardiac involvement is frequent in SSc and is50 60
Patients with skin ulcer
Patients without skin ulcer
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cardiac manifestation in the early stage of the disease as
well as their careful monitoring and follow-up are recom-
mended to counteract their impact on the overall disease
outcome. However, little information is available about
the timing of cardiac involvement.17
We found that dcSSc patients had a greater inflammatory
activation. A different immune pattern with a higher
prevalence of SCl 70 antibodies in patients having dcSSc
and a higher prevalence of ACA antibodies in patients
with lcSSc was reported. Patients with ACA antibodies
showed a greater cardiopulmonary involvement suggest-
ing a worse prognosis. However, because of the low
number of patients, we need more data to clarify the
prognostic role of antibodies.18,19
The most significant parameter in prediction of outcome
was the presence of skin ulcers.14 We identify patients
with skin ulcers as high-risk patients for cardiac disease.
This confirms the analysis from the EUSTAR database.20
These patients showed an increase in the number of
arrhythmias during the follow-up; they mainly developed
atrial fibrillation and supraventricular arrhythmias.
Arrhythmias are associated with poor outcome and rep-
resent 6% of the overall causes of death in the large
EULAR Scleroderma Trials and Research database.21,22
In addition, our population of patients with skin ulcers
showed a greater cardiac dysfunction involving both left
and right sides of the heart and a greater deterioration of
cardiac function over the follow-up.
In conclusion, cardiac involvement occurs frequently in
SSc, can manifest in various ways and it is associated with
a poor prognosis. There is little evidence on how best to
detect and manage this fearful complication in SSc.
According to our results, patients with skin ulcers are
patients with high-risk profile of cardiovascular events
and need a tight follow-up. A multidisciplinary cardior-
heumatologic team is necessary to identify these high-
risk patients.
Additional research by large population-based studies is
needed in order to identify possible subsets of SSc patients
at increased risk of cardiopulmonary complications.
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